[{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Organicell Flow","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell Regenerative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Organicell Flow","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell Regenerative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Organicell Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Zofin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Organicell Regenerative Medicine \/ Organicell","highestDevelopmentStatusID":"7","companyTruncated":"Organicell Regenerative Medicine \/ Organicell"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Zofin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell Regenerative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Regenerative Care Network","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Zofin","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Organicell Regenerative Medicine \/ Organicell","highestDevelopmentStatusID":"5","companyTruncated":"Organicell Regenerative Medicine \/ Organicell"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Zofin","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell Regenerative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Zofin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell Regenerative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Amniotic fluid derived microRNAs","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Organicell Regenerative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Beauty Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Exosome Based Therapeutic","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Organicell Regenerative Medicine \/ Beauty Health","highestDevelopmentStatusID":"1","companyTruncated":"Organicell Regenerative Medicine \/ Beauty Health"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Human Amniotic Fluid","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell Regenerative Medicine \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Organicell Regenerative Medicine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Zofin is an acellular, minimally manipulated product, derived from human amniotic fluid (HAF). This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from amniotic stem and e...

                          Brand Name : Zofin

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 17, 2022

                          Lead Product(s) : Human Amniotic Fluid

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Exosomes are small membrane vesicles, which are among the most productive and conducive to wound healing and countering inflammation. The benefits will help treat the skin and address signs of aging when delivered as a booster through Hydrafacial’s exc...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 14, 2022

                          Lead Product(s) : Exosome Based Therapeutic

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Sponsor : Beauty Health

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Zofin™ is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to SARS related to COVID-19 infection vs placebo.

                          Brand Name : Zofin

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 11, 2021

                          Lead Product(s) : Amniotic fluid derived microRNAs

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The expanded access protocol provided access to the investigational product, Zofin, for patients in outpatient and inpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19 infection, or who are judged by a healthcare provider to b...

                          Brand Name : Zofin

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 22, 2021

                          Lead Product(s) : Zofin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent.

                          Brand Name : Zofin

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 29, 2020

                          Lead Product(s) : Zofin

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicell’s lead therapeutic, Zofin™, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF.

                          Brand Name : Zofin

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 20, 2020

                          Lead Product(s) : Zofin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : IND Enabling

                          Recipient : Regenerative Care Network

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Aside from Convalescent Plasma, Zofin, is the first reported acellular therapy which can be accessed under FDA’s approved expanded access program.

                          Brand Name : Zofin

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 29, 2020

                          Lead Product(s) : Zofin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The objective of the FDA phase I/II study is to investigate the safety and potential efficacy of perinatal sourced components for COVID-19. The study will enroll 20 patients and is expected to commence within the next two weeks.

                          Brand Name : Zofin

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 18, 2020

                          Lead Product(s) : Zofin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Alternative Research Associates

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Treatment with Organicell Flow resulted in a remarkable improvement in their clinical status, lung and renal function confirmed by follow up chest X-rays and lab data.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 27, 2020

                          Lead Product(s) : Organicell Flow

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : This trial will be the first randomized, double-blinded, placebo-controlled, phase I/II multi-center trial investigating the safety and efficacy of amniotic fluid sourced components for COVID-19.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 05, 2020

                          Lead Product(s) : Organicell Flow

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank